The mechanisms underlying the poor response may include the lower PD-L1 expression, lower tumor mutational burden (TMB), and the immunosuppressive tumor microenvironment (TME) resulting from constitutive activation of the EGFR signaling pathway in EGFR-mutated NSCLC [65,68]. Here, EGFR is linked to non-small cell lung carcinoma.